Jump to Navigation
Home

Main menu

  • Home
  • Latest Stories
  • Markets Map
  • Trends and Sentiments
  • Leading Topics
  • News Search
  • Comments and Analysis

Secondary menu

  • Latest News
  • Top Rated
  • Most Popular
  • Archive
  • About Us
  • Is Your Credit Card Less Secure Than Ever Before?
  • Glacier Bancorp's (GBCI) CEO Randall Chesler on Q1...
  • Chemed's (CHE) CEO Kevin McNamara on Q1 2018 Results...
  • Trade war 'extremely dangerous' for global...
  • US said to investigate AT&T and Verizon over wireless...
  • Picture-perfect forgery? Art world awaits court decision...
  • ‘Eat SHYTE’: How this Ontario man’s chocolate brand...
  • Sergio Garcia lost his cool after a bad shot and threw...
  • Come see Henry Blodget break down VR, AR, and AI at the...
  • What are the odds an ex-fighter pilot like Capt. Tammie...

    A.P. Pharma: Side Effect Issue With Competitive Drug Is A Huge Positive

    Mon, 07/02/2012 - 07:18 EDT - Seeking Alpha
    • APPA.OB
    • DNDN
    • HGSI
    • Smith On Stocks

    By Smith On Stocks:
    Investment Thesis
    The FDA issued a safety communication on June 29, 2012 further advising physicians on the link of ondansetron (Zofran) to QT interval prolongation; this condition can cause abnormal heart rhythms that in some cases may be life threatening. This follows a previous communication on the same concern on September 11, 2011. Because AP Pharma's (APPA.OB) competitive product in development, APF530, is not linked to QT interval prolongation, this gives APF530 a meaningful differentiation from ondansetron in terms of safety. In addition, ondansetron can no longer be given as a single 32 mg infusion and will now have to be given in roughly three infusions over a twelve hour period. Some contacts I have spoken with think that these factors will cause a major erosion in ondansetron sales. If their assessment is correct, this could be a huge positive for A.P. Phama as ondansetron currently accounts for one thirdComplete Story »

    • Original article
    • Login to post comments
     

    Related

    • FDA Issues Warning That Misuse, Abuse Of Imodium Can Cause Heart Issues

      Following reports that some opioid addicts are taking potentially lethal doses of over-the-counter anti-diarrhea medication, the Food and Drug Administration has issued a warning about the dangers of abuse and misuse of these seemingly innocuous products.

    • FDA Warns Of Rare, Potentially Dangerous Hypersensitivity To Popular Acne Products

      (Paxton Holley)

    • After FDA Warning, Kim Kardashian Posts Corrected Endorsement Of Morning Sickness Pill

    • FDA Approves First “Biosimilar” Drug. Could Drive Down Cost Of Most Expensive Medications

      (D O’Quinn)

    • A Writer Linked To Underground Hackers Is Going To Prison For Threatening An FBI Agent

      An activist and writer linked to the hacking collective Anonymous was sentenced to prison on Thursday for threatening an FBI agent and helping share stolen data, marking the end of a criminal case criticized by free-speech advocates.

    • Dick Cheney Once Feared Terrorists Might Wirelessly Send A Fatal Shock To His Heart

      Cheney had heart device partially disabled to prevent a terrorist from sending a fatal shock WASHINGTON (AP) — Former Vice President Dick Cheney says he once feared that terrorists could use the electrical device that had been implanted near his heart to kill him and had his doctor disable its wireless function.

    • Salads Sold At Red Lobster & Olive Garden Linked To Cyclospora Outbreaks In Two States

      (Morton Fox)

    • A.P. Pharma: PDUFA Date On APF530 Looms And I Am A Buyer

      By Smith On Stocks: Investment Opinion and Background

    • Cash Infusions Provide Needed Financial Strength For Discovery Laboratories

      By Smith On Stocks: Report Summary

    • Vibex MTX: The Cherry On Top Of The Antares Investment Story

      By Smith On Stocks: Investment Thesis

    Latest

    Picture-perfect forgery? Art world awaits court decision on alleged Norval Morrisseau fraud ring
    Picture-perfect forgery? Art world awaits court...
    ‘Eat SHYTE’: How this Ontario man’s chocolate brand became famous in the U.K.
    ‘Eat SHYTE’: How this Ontario man’s chocolate...

    Markets Map

    Markets Map

    Follow Us

    Follow Us on Facebook, Twitter, Google Plus and RSS LinkedIn Facebook Twitter Google Plus RSS
    S&P 500: 2579.37 0.16% FTSE: 7487.96 -0.07% Nikk.: 22420.08 1.82% DAX: 13465.51 1.75% HSI: 28594.06 1.22% FX: EUR/GBP: 1.1401 USD/EUR: 1.1618 JPY/USD: 114.1510 Commodities: Gold: 1276.1000

    Bullfax.com - Market News & Analysis 2008-2011
    Contact Us | About Us | Terms & Conditions

    Follow Us on Facebook, Twitter, Google Plus and RSS LinkedIn Facebook Twitter Google Plus RSS .

    Secondary menu

    • Latest News
    • Top Rated
    • Most Popular
    • Archive
    • About Us